[Dilip Davda] CBPL has shown inconsistency in bottom lines despite growing top lines. With the vaccine product launch plans up the sleeve, it is poised for bright prospects as claimed by the management. However, all these positive factors are discounted in the asking price. Hence only cash surplus, risk savvy investors may consider investment for long term at their own risk. Read detail review...

Chandra Bhagat Pharma IPO Review by Members

Chandra Bhagat Pharma IPO Reviews, analysis and views by popular members. Read Chandra Bhagat Pharma Ltd. IPO reviews by retail investors to find recommended ipo to buy.

Chandra Bhagat Pharma IPO Review Summary by Members

Review By	Apply	May Apply	Neutral	Avoid
Count	0	0	0	0
%	0.00	0.00	0.00	0.00

Member	Review
No recommendation found. Be the first to post the recommendation.

Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.

Chandra Bhagat Pharma IPO Review & Recommendations

Chandra Bhagat Pharma IPO Review Summary from brokers and analysts

Chandra Bhagat Pharma IPO Review by Dilip Davda May apply

Chandra Bhagat Pharma IPO Review by Members

Chandra Bhagat Pharma IPO Review Summary by Members

Read more about Chandra Bhagat Pharma IPO